Welcome to our dedicated page for Prelude Therapeutics SEC filings (Ticker: PRLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. SEC filings for Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company. Through these regulatory documents, investors can review how Prelude describes its business, pipeline, risks, and financial condition as it advances programs such as SMARCA2 and KAT6A degraders, mutant selective JAK2V617F JH2 inhibitors for myeloproliferative neoplasms, and mutant CALR-targeted degrader antibody conjugates (DACs).
Key filings include annual reports on Form 10-K, which provide an overview of Prelude’s precision oncology strategy, target selection, collaborations, and risk factors, and quarterly reports on Form 10-Q, which update on operating expenses, cash runway, and development progress. Current reports on Form 8-K disclose material events such as the exclusive option agreement with Incyte for the JAK2V617F program, expanded arrangements with AbCellera Biologics, clinical portfolio reprioritizations, Nasdaq listing compliance updates, and changes in board or executive roles.
Investors interested in ownership and governance can also use SEC filings to track equity financings, non-voting common stock issuances, and other capital structure changes described in transaction-related 8-Ks and registration statements. These documents outline terms of option agreements, securities purchase agreements, and related registration rights for Prelude’s stock.
On Stock Titan, each new PRLD filing is captured from EDGAR and paired with AI-powered summaries that highlight the most relevant points, such as pipeline focus, collaboration economics, cash position commentary, and listing status updates. This helps readers navigate lengthy reports and quickly locate information on topics like JAK2V617F program economics, SMARCA2 and KAT6A development plans, and the impact of strategic decisions on Prelude’s financial profile.
Use this page to access Prelude Therapeutics’ 10-K, 10-Q, 8-K and related filings, along with concise AI explanations that clarify technical disclosures and regulatory language for PRLD stock watchers.
Prelude Therapeutics filed its annual report detailing a precision oncology pipeline and several major collaborations. Lead JAK2V617F inhibitor PRT12396 has FDA IND clearance, with a Phase 1 study planned for the second quarter of 2026 and an exclusive option deal with Incyte that includes a $100 million option exercise price and up to $910 million in potential cash payments, of which $60 million has already been received. The company is advancing a selective KAT6A degrader toward an IND in mid‑2026 and has expanded a multi‑program degrader antibody conjugate collaboration with AbCellera that delivered $12.5 million in upfront payments plus future milestones and royalties. Prelude paused clinical development of its SMARCA2 degrader program to prioritize resources, while highlighting a broad early‑stage degrader and precision ADC platform and a substantial global patent estate.
Prelude Therapeutics reported 2025 results showing reduced spending and a smaller loss while advancing its oncology pipeline. Revenue was $12.1 million versus $7.0 million in 2024, largely from collaborations. Research and development expenses fell to $94.3 million from $118.0 million, and general and administrative expenses dropped to $22.4 million from $28.7 million, reflecting lower stock-based compensation and discontinued trials.
Net loss narrowed to $99.5 million, or $1.29 per share, compared with $127.2 million, or $1.68 per share, a year earlier. Cash, cash equivalents, restricted cash and marketable securities totaled $106.4 million as of December 31, 2025, which the company expects will fund operations into the second quarter of 2027.
On the pipeline side, the FDA cleared the IND for lead JAK2V617F inhibitor PRT12396, with a Phase 1 trial in high-risk polycythemia vera and myelofibrosis anticipated to start in the second quarter of 2026. KAT6A degrader PRT13722 is in IND-enabling studies, with an IND filing planned for mid-2026 and a Phase 1 study expected in the second half of 2026. Prelude also expanded its degrader antibody conjugate collaboration with AbCellera and highlighted early mCALR-targeted DAC work, while maintaining an exclusive option agreement with Incyte for the JAK2V617F program.
Prelude Therapeutics Inc. insider ownership update: Krishna Vaddi reported beneficial ownership of 6,745,647 shares of Prelude Therapeutics common stock, representing 13.15% of the class as of December 31, 2025. This includes directly held shares, stock options exercisable within 60 days, and shares held through Sidus Ventures, LLC and several trusts for which he is deemed to have beneficial ownership.
Prelude Therapeutics reported a stock option grant to Chief Chemistry Officer Andrew Combs. On February 4, 2026, he received an employee stock option covering 230,000 shares of common stock at an exercise price of $2.30 per share.
The option vests over four years: 25% of the shares vest on February 4, 2027, and the remaining 75% vest in equal monthly installments (1/48 of the total shares) until fully vested, as long as Combs continues providing service to the company on each vesting date.
Prelude Therapeutics reported that Chief Scientific Officer Peggy Scherle received an employee stock option grant on February 4, 2026. The derivative award covers 230,000 shares of common stock at an exercise price of $2.30 per share, with no cash paid for the option itself.
The option vests over time: 25% of the total shares vest on February 4, 2027, and the remaining shares vest in equal monthly installments of 1/48 of the total until fully vested. Following this grant, Scherle beneficially holds 230,000 stock options, all reported as directly owned.
Prelude Therapeutics granted its CLO, CFO and Corporate Secretary Bryant D. Lim an employee stock option covering 275,000 shares of common stock on February 4, 2026. The option has an exercise price of $2.30 per share and is held as a direct ownership position.
The award vests over four years: 25% of the shares vest on February 4, 2027, and the remaining 75% vest in equal monthly installments of 1/48 of the total grant until fully vested, conditioned on Mr. Lim continuing to provide services to the company on each vesting date.
Prelude Therapeutics CEO Krishna Vaddi received a large stock option grant. The Form 4 reports an employee stock option to purchase 837,000 shares of Prelude Therapeutics common stock at an exercise price of $2.30 per share, granted on February 4, 2026.
The option expires on February 3, 2036. It vests 25% on February 4, 2027, then 1/48 of the total shares vests monthly until fully vested, as long as Vaddi continues providing services to the company on each vesting date.
Prelude Therapeutics reported that the U.S. Food and Drug Administration has cleared it to begin a Phase 1 study of PRT12396. This drug is described as a mutant-selective JAK2V617F inhibitor being developed to treat patients with certain myeloproliferative neoplasms, a group of blood cancers. The update was shared via a press release furnished as an exhibit to the report.
Prelude Therapeutics Incorporated furnished an update for investors by making new presentation materials available. The company plans to use this investor presentation in meetings beginning on January 9, 2026, and has attached the materials as Exhibit 99.1. The information in the presentation and the related report is being furnished rather than filed, which means it is not subject to certain liability provisions and is not automatically incorporated into other securities offering documents.